Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

FGFR4 inhibitor

DRUG CLASS:

FGFR4 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

FGF19 overexpression	Hepatocellular Cancer	FGF19 overexpression	Hepatocellular Cancer	ABSK011 Sensitive: C2 – Inclusion Criteria ABSK011 Sensitive : C2	ABSK011 Sensitive: C2 – Inclusion Criteria ABSK011 Sensitive : C2
FGF19 positive	Hepatocellular Cancer	FGF19 positive	Hepatocellular Cancer	BLU-554 Sensitive: C3 – Early Trials BLU-554 Sensitive : C3	BLU-554 Sensitive: C3 – Early Trials BLU-554 Sensitive : C3
FGF19 negative	Hepatocellular Cancer	FGF19 negative	Hepatocellular Cancer	BLU-554 Resistant: C3 – Early Trials BLU-554 Resistant : C3	BLU-554 Resistant: C3 – Early Trials BLU-554 Resistant : C3
FGF19 overexpression	Hepatocellular Cancer	FGF19 overexpression	Hepatocellular Cancer	BLU-554 Sensitive: C3 – Early Trials BLU-554 Sensitive : C3	BLU-554 Sensitive: C3 – Early Trials BLU-554 Sensitive : C3
FGF19 positive	Hepatocellular Cancer	FGF19 positive	Hepatocellular Cancer	H3B-6527 Sensitive: C3 – Early Trials H3B-6527 Sensitive : C3	H3B-6527 Sensitive: C3 – Early Trials H3B-6527 Sensitive : C3
FGFR4 expression	Hepatocellular Cancer	FGFR4 expression	Hepatocellular Cancer	PDR001 + FGF401 Sensitive: C3 – Early Trials PDR001 + FGF401 Sensitive : C3	PDR001 + FGF401 Sensitive: C3 – Early Trials PDR001 + FGF401 Sensitive : C3
KLB expression	Hepatocellular Cancer	KLB expression	Hepatocellular Cancer	PDR001 + FGF401 Sensitive: C3 – Early Trials PDR001 + FGF401 Sensitive : C3	PDR001 + FGF401 Sensitive: C3 – Early Trials PDR001 + FGF401 Sensitive : C3
FGF19 positive	Hepatocellular Cancer	FGF19 positive	Hepatocellular Cancer	sugemalimab + BLU-554 Sensitive: C3 – Early Trials sugemalimab + BLU-554 Sensitive : C3	sugemalimab + BLU-554 Sensitive: C3 – Early Trials sugemalimab + BLU-554 Sensitive : C3
FGF19 overexpression	Hepatocellular Cancer	FGF19 overexpression	Hepatocellular Cancer	FGF401 Sensitive: D – Preclinical FGF401 Sensitive : D	FGF401 Sensitive: D – Preclinical FGF401 Sensitive : D
FGF19 overexpression	Hepatocellular Cancer	FGF19 overexpression	Hepatocellular Cancer	H3B-6527 Sensitive: D – Preclinical H3B-6527 Sensitive : D	H3B-6527 Sensitive: D – Preclinical H3B-6527 Sensitive : D
FGF19 overexpression	Hepatocellular Cancer	FGF19 overexpression	Hepatocellular Cancer	palbociclib + H3B-6527 Sensitive: D – Preclinical palbociclib + H3B-6527 Sensitive : D	palbociclib + H3B-6527 Sensitive: D – Preclinical palbociclib + H3B-6527 Sensitive : D
FGFR4 amplification	Clear Cell Renal Cell Carcinoma	FGFR4 amplification	Clear Cell Renal Cell Carcinoma	BLU 9931 Sensitive: D – Preclinical BLU 9931 Sensitive : D	BLU 9931 Sensitive: D – Preclinical BLU 9931 Sensitive : D